While Moderna is running at full speed with vaccine sales, manufacturing and distribution, its emergency use authorization limits its marketing and brand efforts. Moderna submitted for full approval June 1, but the FDA has not indicated how quickly it will act. Moderna CEO Stéphane Bancel said in the hiring announcement that he looks forward to working with Cronin "to amplify Moderna's story and the promise of mRNA science for patients." One step already recently cinched up is the vaccine's brand name Spikevax, now approved in Europe.